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OBJECTIVES: IDA/IDS is common in pregnancy, postpartum, inﬂ ammatory bowel 
disease, chronic kidney disease, chronic heart failure, menorrhagia/hypermenorrhagia, 
cancer and following surgery. We estimate the BI associated with substituting iron 
sucrose (standard) with ferric carboxymaltose (new treatment), which allows for the 
application of higher dosages in a shorter time. The analysis adopted the perspective 
of the Swiss mandatory health insurance (MHI) covering the above indications and is 
based on real-life data to verify the hypothetical BI estimated prior to launch. 
METHODS: Resource use (no. of patients, dosage per application, no. of applications) 
was based on recent primary data (Polyquest Prescriber Analysis, Anemia Patient 
Record Study in Switzerland). Personnel costs were estimated using the Swiss Tarmed 
fee-for-service reimbursement system. Drug costs and costs of materials used were 
based on ofﬁ cial tariffs (Spezialitätenliste, MiGeL). Real-life IMS sales data of both 
products were used to verify the BI model. RESULTS: Ferric carboxymaltose was 
associated with cost savings of 30–44% compared to iron sucrose based on costs of 
CHF 101/ 210/ 420 and CHF 144/ 375/ 721 per 200/ 500/ 1000 mg treatment cycle, 
respectively. This leads to cost savings of CHF 15–33 million per year to the Swiss 
MHI across all indications in the ﬁ rst 3 years post-launch, due to reductions in person-
nel costs. Ferric carboxymaltose was shown to be cost-saving in all indications except 
dialysis (due to ﬂ at-fee reimbursement). Sensitivity analyses showed the amount of 
cost savings to be sensitive to changes in the number of inpatients (10–20% of total) 
treated with intravenous iron (due to ﬂ at-fee reimbursement). CONCLUSIONS: Treat-
ing IDA/IDS involves substantial costs to the Swiss MHI. Substitution of iron sucrose 
with ferric carboxymaltose may help to reduce these due to reduced personnel costs. 
This novel type of real-life BIA will be of increasing interest as conditional reimburse-
ment increases.
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OBJECTIVES: To compare the health care costs 6 months prior to and 6 months after 
initiation of pregabalin in difﬁ cult-to-treat neuropathic pain (NeP) patients. 
METHODS: This was a retrospective longitudinal database study in NeP patients 
from the South-West region of Sweden (1.5 million inhabitants). Individual patient 
data from the 1st of January 2000 on health care visits (outpatient, inpatient, primary 
care), costs, mortality and diagnoses were included. Data from the Swedish Prescribed 
Drug register were included from July 1, 2005 until December 31, 2007. Difﬁ cult-to-
treat NeP was deﬁ ned as patients with a NeP diagnosis in 2006, who had had 2 
prescriptions of at least three pain medications during one year from the index diag-
nosis date. The patients should also have had two or more prescriptions of pregabalin 
preceded by at least a six months pregabalin naïve period. RESULTS: A total of 462 
difﬁ cult-to-treat NeP patients met the above criteria and were included in the analyses. 
There was a statistically signiﬁ cant reduction in NeP related costs (visits registered 
with a NeP diagnosis) after initiation of pregabalin (p = 0.0042 Mann-Whitney). The 
mean per patient NeP related costs were SEK17,684 (c1,845) 6 months before and 
SEK10,642 (c1,110) 6 months after pregabalin initiation. The mean non-NeP related 
costs before treatment (SEK46,095; c4,809) did not differ signiﬁ cantly from the 
non-NeP costs after treatment (SEK 51,632; c5,387), p = 0.8016. The number of 
NeP-related in-patient visits, primary care visits and the number of days in hospital 
decreased signiﬁ cantly (p = 0.0475, p = 0.0129, p = 0.0179, respectively) after treat-
ment with pregabalin. CONCLUSIONS: Initiation of pregabalin signiﬁ cantly reduced 
the NeP related health care costs in the 6-month period following initiation. Of note 
was the non signiﬁ cant difference in non-NeP related costs, probably reﬂ ecting the 
on-going costs associated with management of the patients’ concurrent conditions, eg, 
diabetes.
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OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for 
chronic low back pain (CLBP). METHODS: Study sample was selected from a U.S. 
privately-insured claims database (2004–2008). Selection criteria: ages 18–64 years, 
had a low back pain (LBP) diagnosis (per HEDIS speciﬁ cations) with a subsequent 
CLBP-qualifying diagnosis recorded 90 days or more after the initial LBP diagnosis. 
Duloxetine-treated patients had ≥1 duloxetine prescription within 6 months after 
CLBP diagnosis, no prior duloxetine claim, and continuous eligibility ≥12 months 
before ﬁ rst LBP diagnosis and ≥6 months after index duloxetine prescription (study 
period). 553 duloxetine-treated patients were matched to a total of 553 control 
patients who initiated another non-surgical LBP treatment based on propensity score 
and time from ﬁ rst LBP diagnosis to treatment initiation. a subset (n = 103 each) of 
matched employees was also analyzed. McNemar tests were used to compare LBP 
treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and 
drug) costs from third-party payer perspective and employee indirect (workloss) costs. 
RESULTS: During the 6-month study period, matched duloxetine-treated patients had 
signiﬁ cantly lower rates of other pharmacological therapy than controls (e.g., 56.2% 
vs. 64.9% narcotic opioids, p = 0.002; 34.9% vs. 49.5% NSAIDs; P < 0.001) and 
non-invasive therapy (28.8% vs. 38.5% chiropractic therapy; 25.5% vs. 35.4% physi-
cal therapy; 17.5% vs. 28.4% exercise therapy; all P < 0.001). Duloxetine-treated 
patients versus controls had numerically lower back surgery rates (2.2% vs. 3.8%, p 
= 0.117) and similar direct costs ($7658 vs. $7439, p = 0.812). Among CLBP employ-
ees, duloxetine-treated employees versus controls had lower rates of other non-surgical 
therapy, numerically lower back surgery rates (0% vs. 3.9%, p = 0.125), lower total 
direct and indirect costs ($5227 vs. $7229, p = 0.042), and numerically lower indirect 
costs ($1806 vs. $2664, p = 0.053). CONCLUSIONS: Duloxetine treatment in CLBP 
patients/employees versus other non-surgical treatment was associated with reduced 
rates of non-surgical therapies and numerically lower surgery rates without increased 
costs.
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OBJECTIVES: To estimate the prevalence of constipation concomitant to opioid 
treatment and related resource utilization and costs from the private payer perspective. 
METHODS: Patients on opioid therapy were identiﬁ ed from a longitudinal insurance 
claims database consisting in 1,057,033 individuals for a period of 35 months. An 
algorithm was used to identify patients on opioid therapy with coincident constipa-
tion-related claims according to ICD-10 codes, targeted procedures and opioid use 
criteria. Resource utilization and costs were determined for these individuals and 
compared with patients on opioid therapy without constipation, without opioid 
therapy with constipation and without both conditions. Results were compared using 
ANOVA with a signiﬁ cance level of 0.05 and are presented per individual per month. 
RESULTS: A total of 23,313 patients were classiﬁ ed as opioid treated patients (2.21% 
of total population) and 6,678 had events related to constipation (29.03% of the 
opioid population). Compared with opioid treated patients without constipation, 
incremental mean total costs per month per patients with the condition were 261.18 
BRL (P < 0.001). The average cost per month for opioid-related constipation patients 
was 787.84 BRL, signiﬁ cantly higher than patients on opioid therapy without consti-
pation (526.66 BRL), with no opioid therapy but constipated (284.47 BRL) and 
without both (90.17 BRL) (P < 0.001 for all comparisons). Patients with claims related 
to both conditions had signiﬁ cantly more days in hospital per month (0.25 vs. 0.497, 
P < 0.001), outpatient ofﬁ ce visits (1.04 vs. 1.59, P < 0.001), outpatient procedures 
(4.69 vs. 14.05, P < 0.001) and tests and therapies (31.95 vs. 36.66, P < 0.001) than 
did patients without opioid-related constipation claims. CONCLUSIONS: The eco-
nomic burden of patients with constipation events coincident with opioid treatment 
is signiﬁ cantly higher when compared to all other groups. Constipated patients 
without opioid therapy had also higher costs than those free of both conditions. These 
results indicate that reducing opioid-induced constipation has potential cost savings 
for the health care system.
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OBJECTIVES: This study compared self-reported pain scores among patients with 
major depressive disorder (MDD) in the U.S. Veterans Affairs (VA) health system 
treated with duloxetine versus other antidepressants. METHODS: The electronic 
medical records between October 1, 2004 and October 31, 2008 were obtained from 
the VA Veterans Integrated Service Network 16 data warehouse. All patients treated 
with either duloxetine monotherapy or other antidepressants (non-duloxetine) were 
selected. The ﬁ rst dispense date of the index agent was deﬁ ned as the index date. All 
patients must have: 1) 1 + prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3); 2) no 
prior diabetes (ICD-9-CM: 250.xx) or bipolar (ICD-9-CM: 296.4x-296.8x) diagnosis; 
and 3) self-reported pain score measured within 60 days both before the index date 
(baseline pain score) and after the last dispense date of the index antidepressants 
during the 12-month post-index period. The non-duloxetine-treated patients were 
matched to the duloxetine-treated patients via propensity scoring (1:1 ratio), control-
ling for demographics, comorbidities, prior opioid use, prior health care utilization, 
and baseline pain scores. Opioid utilization and pain scores over the 12-month post-
index period were examined between cohorts. RESULTS: The study sample included 
210 duloxetine- and 210 non-duloxetine-treated patients. Signiﬁ cantly less duloxetine-
treated patients than non-duloxetine-treated patients used opioids (20.1%; vs. 34.3%, 
p = .002) over the 12-month post-index period. Both cohorts had similar morphine-
equivalent opioid daily use and pain scores during the follow-up period. Controlling 
for baseline pain scores and medication duration, duloxetine-treated patients had 1.58 
